Vascular Biogenics Company Profile (NASDAQ:VBLT)

About Vascular Biogenics

Vascular Biogenics logoVascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VBLT
  • CUSIP:
Key Metrics:
  • Previous Close: $5.80
  • 50 Day Moving Average: $5.31
  • 200 Day Moving Average: $4.89
  • 52-Week Range: $3.03 - $7.58
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.79
  • P/E Growth: 0.00
  • Market Cap: $155.88M
  • Outstanding Shares: 26,875,000
  • Beta: -3.27
Profitability:
  • Return on Equity: -35.53%
  • Return on Assets: -32.27%
Debt:
  • Current Ratio: 13.13%
  • Quick Ratio: 13.13%
Additional Links:
Companies Related to Vascular Biogenics:

Analyst Ratings

Consensus Ratings for Vascular Biogenics (NASDAQ:VBLT) (?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.40 (131.03% upside)

Analysts' Ratings History for Vascular Biogenics (NASDAQ:VBLT)
Show:
DateFirmActionRatingPrice TargetDetails
2/21/2017Piper Jaffray CompaniesReiterated RatingOverweight$11.00View Rating Details
12/1/2016Roth CapitalReiterated RatingBuy$17.00View Rating Details
11/29/2016Chardan CapitalSet Price TargetBuy$20.00View Rating Details
11/14/2016HC WainwrightReiterated RatingBuyView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$16.00 -> $8.00View Rating Details
11/13/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformView Rating Details
(Data available from 2/22/2015 forward)

Earnings

Earnings History for Vascular Biogenics (NASDAQ:VBLT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/27/2017        
11/10/2016Q316($0.15)($0.12)ViewN/AView Earnings Details
8/15/2016Q2($0.23)($0.14)ViewListenView Earnings Details
5/13/2016Q1($0.21)($0.21)ViewListenView Earnings Details
3/29/2016Q4($0.32)($0.14)ViewListenView Earnings Details
11/12/2015Q315($0.19)($0.29)ViewListenView Earnings Details
8/13/2015Q215($0.19)($0.15)ViewListenView Earnings Details
5/12/2015Q115($0.19)($0.15)ViewListenView Earnings Details
3/25/2015($0.24)($0.25)ViewN/AView Earnings Details
11/14/2014($0.41)($4.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vascular Biogenics (NASDAQ:VBLT)
Current Year EPS Consensus Estimate: $-0.66 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.15)($0.15)($0.15)
Q4 20161($0.16)($0.16)($0.16)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vascular Biogenics (NASDAQ:VBLT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vascular Biogenics (NASDAQ:VBLT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Vascular Biogenics (NASDAQ:VBLT)
DateHeadline
investopedia.com logoVBL's Thyroid Cancer Drug Clears Phase 2 (VBLT) (NASDAQ:VBLT)
www.investopedia.com - February 22 at 10:46 AM
us.rd.yahoo.com logoVBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer (NASDAQ:VBLT)
us.rd.yahoo.com - February 22 at 10:46 AM
investopedia.com logoVBL Therapeutics Thyroid Cancer Drug Clears Phase 2 (NASDAQ:VBLT)
www.investopedia.com - February 22 at 10:46 AM
streetinsider.com logoPiper Jaffray Reiterates Overweight Rating and $11 PT on Vascular Biogenics (VBLT); Phase 2a Thyroid Cancer Drug ... - StreetInsider.com (NASDAQ:VBLT)
www.streetinsider.com - February 21 at 4:25 PM
News IconABR Of Vascular Biogenics Ltd. (NASDAQ:VBLT) Stock At 1 - Stock Observer (NASDAQ:VBLT)
www.thestockobserver.com - February 19 at 8:18 AM
News IconVascular Biogenics Ltd VBLT Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:VBLT)
www.bioportfolio.com - February 14 at 6:53 AM
finance.yahoo.com logoVBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference (NASDAQ:VBLT)
finance.yahoo.com - February 6 at 10:39 AM
kcregister.com logoVascular Biogenics Ltd. (NASDAQ:VBLT) published a paper discussing MOSPD2, a potential novel immuno-oncology ... - KC Register (NASDAQ:VBLT)
www.kcregister.com - February 3 at 6:35 AM
News IconAverage Directional Index in Review for Vascular Biogenics Ltd ... - Sherwood Daily (NASDAQ:VBLT)
sherwooddaily.com - February 2 at 6:33 AM
us.rd.yahoo.com logoVBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target (NASDAQ:VBLT)
us.rd.yahoo.com - February 1 at 7:17 AM
News IconReviewing Individual Broker Targets Of Vascular Biogenics Ltd. (VBLT) - NewsDen (NASDAQ:VBLT)
newsden.net - January 31 at 7:35 AM
News IconRelative Strength Index Review on Shares of Vascular Biogenics Ltd. (VBLT) - Sherwood Daily (NASDAQ:VBLT)
sherwooddaily.com - January 31 at 7:35 AM
News IconTechnical Action Update on Shares of Vascular Biogenics Ltd. (VBLT) - Sherwood Daily (NASDAQ:VBLT)
sherwooddaily.com - January 27 at 6:34 AM
News IconEarnings in Full Force, Analysts Take Aim at Vascular Biogenics Ltd. (NASDAQ:VBLT) - Wall Street Beacon (NASDAQ:VBLT)
wsbeacon.com - January 25 at 9:18 PM
News IconTrading Corner: Eye on Technical Levels for Vascular Biogenics Ltd. (VBLT) - Sherwood Daily (NASDAQ:VBLT)
sherwooddaily.com - January 25 at 9:18 PM
investornewswire.com logoVascular Biogenics Ltd. (NASDAQ:VBLT) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:VBLT)
www.investornewswire.com - January 22 at 8:16 PM
News IconStock Tracker: Earnings & Estimates for Vascular Biogenics Ltd. (NASDAQ:VBLT) - Aiken Advocate (NASDAQ:VBLT)
aikenadvocate.com - January 18 at 5:28 AM
News IconWill The Needle Move For Vascular Biogenics Ltd. (NASDAQ:VBLT) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:VBLT)
wsbeacon.com - January 18 at 5:28 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Vascular Biogenics Ltd. (NASDAQ:VBLT) - Wall Street Beacon (NASDAQ:VBLT)
wsbeacon.com - January 16 at 12:30 PM
finance.yahoo.com logoVBL Therapeutics Provides Year End 2016 Corporate Update (NASDAQ:VBLT)
finance.yahoo.com - January 10 at 4:47 AM
publicnow.com logoVBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study (NASDAQ:VBLT)
www.publicnow.com - January 7 at 6:21 AM
investornewswire.com logoVascular Biogenics Ltd. (NASDAQ:VBLT) Strong Buy Recommendations At 3 - Investor Newswire (NASDAQ:VBLT)
www.investornewswire.com - December 31 at 8:16 PM
News IconStock ABR Of Vascular Biogenics Ltd. (NASDAQ:VBLT) At 1 - Stock Observer (NASDAQ:VBLT)
www.thestockobserver.com - December 31 at 8:16 PM
News IconVascular Biogenics Ltd. (VBLT) Under Analyst Spotlight - UK Market ... - UK Market News (NASDAQ:VBLT)
www.ukmarketnews.co.uk - December 28 at 8:25 AM
News IconCCI Level Check for Vascular Biogenics Ltd. (VBLT) - Yankee Analysts (NASDAQ:VBLT)
yankeeanalysts.com - December 16 at 6:20 AM
News IconInvestor Corner: Checking the Charts for Vascular Biogenics Ltd. (VBLT) - Yankee Analysts (NASDAQ:VBLT)
yankeeanalysts.com - December 15 at 7:05 AM
News IconTrading Insight: Taking a Look at Levels for Vascular Biogenics Ltd. (VBLT) - Yankee Analysts (NASDAQ:VBLT)
yankeeanalysts.com - December 14 at 8:19 AM
News IconVascular Biogenics Ltd. (NASDAQ:VBLT) Stock ABR At 1 - Stock Observer (NASDAQ:VBLT)
www.thestockobserver.com - December 10 at 7:35 PM
us.rd.yahoo.com logoVBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM (NASDAQ:VBLT)
us.rd.yahoo.com - December 5 at 8:24 AM
us.rd.yahoo.com logo7:02 am Vascular Biogenics announces that the independent DSMC recommended that the Phase 3 GLOBE study investigating ofranergene obadenovec in recurrent glioblastoma study continue as planned (NASDAQ:VBLT)
us.rd.yahoo.com - December 5 at 8:24 AM
News IconTechnical Investor Update on Shares of Vascular Biogenics Ltd. (VBLT) - StockTalk Daily (NASDAQ:VBLT)
stocktalkdaily.com - December 4 at 8:19 AM
streetinsider.com logoVBL Therapeutics (VBLT) Reports $20M at the Market Offering of Ordinary Shares (NASDAQ:VBLT)
www.streetinsider.com - December 2 at 10:26 AM
capitalcube.com logoVascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016 (NASDAQ:VBLT)
www.capitalcube.com - December 1 at 8:47 PM
fxpips.com logoActive Stocks Rising Up Now – SGOC, ISIG, WGBS, COGT, VBLT, THO, NYMX (NASDAQ:VBLT)
www.fxpips.com - December 1 at 8:01 AM
streetinsider.com logoRoth Capital Affirms Vascular Biogenics (VBLT) at 'Buy' Following Topline VB-111 Phase 2 Data (NASDAQ:VBLT)
www.streetinsider.com - November 29 at 4:01 PM
streetinsider.com logoRoth Capital Affirms Vascular Biogenics (VBLT) at 'Buy' Following Topline VB-111 Phase 2 Data (NASDAQ:VBLT)
www.streetinsider.com - November 29 at 4:01 PM
schaeffersresearch.com logoAnalyst Update: Mallinckrodt PLC, Alexion Pharmaceuticals, Inc., and Vascular Biogenics Ltd (NASDAQ:VBLT)
www.schaeffersresearch.com - November 29 at 4:01 PM
schaeffersresearch.com logoAnalyst Update: Mallinckrodt PLC, Alexion Pharmaceuticals, Inc., and Vascular Biogenics Ltd (NASDAQ:VBLT)
www.schaeffersresearch.com - November 29 at 4:01 PM
nasdaq.com logoPre-Market Most Active for Nov 29, 2016 : MT, VALE, ASML, BAC, PBR, CHK, FCX, FOLD, NVLS, ARIA, AAPL, VBLT - Nasdaq (NASDAQ:VBLT)
www.nasdaq.com - November 29 at 12:40 PM
finance.yahoo.com logoVBL Therapeutics Announces Overall Survival Data for VB-111 Monotherapy in Phase 2 Study for Recurrent Thyroid Cancer (NASDAQ:VBLT)
finance.yahoo.com - November 29 at 12:40 PM
finance.yahoo.com logo7:02 am VBL Therapeutics announces top-line results from its exploratory Phase 2 study of VB-111 (ofranergene obadenovec) in patients with advanced, differentiated thyroid cancer (NASDAQ:VBLT)
finance.yahoo.com - November 29 at 12:40 PM
News IconStock Watch: Indicators in View for Vascular Biogenics Ltd. (VBLT) - StockTalk Daily (NASDAQ:VBLT)
stocktalkdaily.com - November 27 at 10:02 AM
News IconVascular Biogenics Ltd. (VBLT) – Latest Broker Consensus - NewsDen (NASDAQ:VBLT)
newsden.net - November 24 at 8:03 PM
News IconWatching Technical Positions on Vascular Biogenics Ltd. (VBLT) - Yankee Analysts (NASDAQ:VBLT)
yankeeanalysts.com - November 23 at 8:23 PM
News IconMarket Focus: Checking Indicators on Shares of Vascular Biogenics Ltd. (VBLT) - MicroCap Wired (NASDAQ:VBLT)
www.microcapwired.com - November 23 at 11:36 AM
finance.yahoo.com logoVBL Therapeutics to Present at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29 (NASDAQ:VBLT)
finance.yahoo.com - November 23 at 11:36 AM
News IconTechnical Watch on These Shares: Vascular Biogenics Ltd. (VBLT) - MicroCap Wired (NASDAQ:VBLT)
www.microcapwired.com - November 22 at 12:58 PM
News IconCheck on Average Directional Index for Vascular Biogenics Ltd. (VBLT) - MicroCap Wired (NASDAQ:VBLT)
www.microcapwired.com - November 21 at 7:46 AM
News IconInvestor Guide: Taking a Look at Indicators for Vascular Biogenics Ltd. (VBLT) - MicroCap Wired (NASDAQ:VBLT)
www.microcapwired.com - November 17 at 7:51 PM
News IconTracking CCI Levels on Shares of Vascular Biogenics Ltd. (VBLT) - Yankee Analysts (NASDAQ:VBLT)
yankeeanalysts.com - November 14 at 8:27 PM

Social

What is Vascular Biogenics' stock symbol?

Vascular Biogenics trades on the NASDAQ under the ticker symbol "VBLT."

Where is Vascular Biogenics' stock going? Where will Vascular Biogenics' stock price be in 2017?

5 equities research analysts have issued 1-year price objectives for Vascular Biogenics' stock. Their predictions range from $8.00 to $20.00. On average, they expect Vascular Biogenics' share price to reach $13.40 in the next year.

When will Vascular Biogenics announce their earnings?

Vascular Biogenics is scheduled to release their next quarterly earnings announcement on Monday, March, 27th 2017.

What are analysts saying about Vascular Biogenics stock?

Here are some recent quotes from research analysts about Vascular Biogenics stock:

  • Piper Jaffray Companies analysts commented, "At the previous Nov '16 update, the study achieved its primary endpoint of 6-month PFS at therapeutic doses, as well as an intriguing overall survival benefit. However, today's update demonstrates a PFS-6 benefit of 47% vs 25% for therapeutic versus sub-therapeutic doses of VB-111, and confirmed a survival benefit, with mOS at 684 days in the therapeutic cohort. We see these results as meaningful in patients who had progressed on prior therapies including TKi's, and the safety and efficacy profile in this third tumor type reduces risk for VB-111 and the broader platform. That said, we don't expect VBL to pursue a Phase IIb/III trial in thyroid at this time, in favor of focusing on ongoing rGBM and soon-to-be-initiated ovarian cancer studies. In advance of clinical updates from those during 2017, we reiterate OW." (2/21/2017)
  • According to Zacks Investment Research, "Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. " (1/12/2017)

Who owns Vascular Biogenics stock?

Vascular Biogenics' stock is owned by many different of retail and institutional investors. Top institutional investors include Franklin Resources Inc. (3.38%), Turner Investments LLC (0.76%) and Menta Capital LLC (0.43%).

Who sold Vascular Biogenics stock? Who is selling Vascular Biogenics stock?

Vascular Biogenics' stock was sold by a variety of institutional investors in the last quarter, including Turner Investments LLC.

Who bought Vascular Biogenics stock? Who is buying Vascular Biogenics stock?

Vascular Biogenics' stock was acquired by a variety of institutional investors in the last quarter, including Menta Capital LLC.

How do I buy Vascular Biogenics stock?

Shares of Vascular Biogenics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Vascular Biogenics stock cost?

One share of Vascular Biogenics stock can currently be purchased for approximately $5.80.

Vascular Biogenics (NASDAQ:VBLT) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Earnings History Chart

Earnings by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Dividend History Chart

Dividend Payments by Quarter for Vascular Biogenics (NASDAQ:VBLT)

Last Updated on 2/22/2017 by MarketBeat.com Staff